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Abstract
The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of
acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide
aberrant splicing events have been recognized as a prominent component of this disease. This review will focus
on how these factors influence drug resistance through altered splicing of tumor suppressor and oncogenes and
dysregulation of the apoptotic signaling network. A better understanding of these factors in disease progression
is necessary to design appropriate therapeutic strategies recognizing specific alternatively spliced or mutated
oncogenic targets.
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Smac/Diablo, Second mitochondria-derived activator of caspase; WT1, Wilms tumor 1; E2F1, E2F transcription factor 1;
VEGF, Vascular endothelial growth factor; AML1-ETO, AML1 and eight twenty-one protein fusion; RBM4, RNA-binding
motif protein 4; U2AF2, U2 small nuclear RNA auxiliary factor 2; WTAP, Wilms tumor 1 associated protein; c-FLIP,
FLICE-like inhibitory protein; BCL-X, Bcl-2-like protein 1; SPF45, Splicing factor 45; CASP8, Caspase-8; CASP9, Caspase-9;
CASP2, Caspase-2; TRAIL, TNF-related apoptosis-inducing ligand; BID, BH3 interacting-domain death agonist;
MCL-1, Myeloid cell leukemia 1; PUMA, p53 upregulated modulator of apoptosis; BAD, BCL2-associated agonist of cell
death; BIK, Bcl2-interacting killer; BAK, Bcl-2 homologous antagonist/killer; HRK, Harakiri, Bcl-2 interacting protein;
XIAP, X-linked inhibitor of apoptosis protein; XAF1, XIAP-associated factor 1; NAIP, Neuronal apoptosis inhibitory protein;
LEDGF, Lens epithelial-derived growth factor
Background
Chemoresistance is a critical challenge in the manage-
ment of acute myeloid leukemia (AML) disease. While
many patients respond well to induction therapy, the
majority relapse due to partial or developed clinical
resistance [1]. In general, AML prognosis is broadly
stratified based on patient age. Patients 60 years old or
younger have a 35–40 % chance of achieving a cure
while those older than 60 have only a 5–15 % chance
[2]. Yet, AML prevalence is much more common among
the elderly with a median age of diagnosis of 69 years
[3]. Older AML patients do not tolerate aggressive treat-
ments as well as younger patients and tend to have more
resistant clonal variants of the disease making it difficult
to achieve a cure [4]. The potential for development of
splice variant specific targeting therapies may help re-
duce treatment toxicity in this older patient population.
The role of gene splicing abnormalities in AML dis-
ease progression and drug resistance has gained atten-
tion as several recent studies have highlighted recurrent
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splice factor mutations as important drivers of hema-
tological malignancies [5]. Splice factors are proteins
that together with at least five small nuclear ribonucleic
acids (RNAs) form part of a dynamic complex called the
spliceosome which splices a nascent RNA transcript at
precise locations to form a mature messenger RNA
(mRNA) sequence that can code for a functional protein
[6]. Splicing is a highly regulated process that can
involve a coordinated action among more than 200 mol-
ecules to favor or repress splicing at specific target sites
[1]. There are two well-known protein families of RNA-
binding splice factors: the serine-rich (SR) proteins that
typically promote exon inclusion and the heterogenous
nuclear ribonucleoproteins (hnRNP) that generally pro-
mote exon skipping [7]. Alternative splicing is an im-
portant part of normal hematopoiesis and is necessary
for cellular differentiation and rapid responses to exter-
nal stimuli [8]. However, imbalances in the splicing
machinery can trigger abnormal programs associated
with malignancies such as myelodysplastic syndromes
(MDS) and AML [9]. As shown in Fig. 1, dysregulation
of splicing mechanisms can affect apoptotic suscept-
ibility in AML and lead to drug resistance.
Recurrent splice factor mutations in myeloid
neoplasms
Next-generation sequencing technologies have revealed a
striking number of myeloid neoplasms harboring splice
factor mutations that alter global splicing events [9]. More
than half of patients with MDS have mutations within
functional components of the spliceosome that are con-
sidered important disease founding events [10]. The most
common recurrent mutations among patients with MDS
are found among the serine-rich SF3B1, SRSF2, and
U2AF1 splice factors [11]. Approximately, 19–28 % of
MDS patients have SF3B1 mutations [12], 12.4 % have
SRSF2 mutations [13], and 6.3 % have U2AF1 mutations
[14]. Splice factor mutations have genome-wide effects
that alter splicing patterns for hundreds of genes. In MDS
patients harboring SF3B1 mutations, 526 genes were
found to be differentially expressed and 2022 genes were
alternatively spliced when compared with CD34+ cells
Fig. 1 Schematic diagram of factors influencing aberrant splicing and drug resistance in AML. TF transcription factor, SF splice factor
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from MDS patients without any splicing mutations [15].
In K562 and TF1 myeloid cell lines with SF3B1, knock-
down 1419 genes were differentially expressed and 384
genes were differentially spliced [15]. In K562 cells
expressing mutant versions of the U2AF1 splice factor,
259–922 genes were differentially spliced depending on
the type of mutation [16]. Intriguingly, only 17 % of the
alternate splicing events detected in K562 cells with
U2AF1 mutants overlapped with those detected in sam-
ples from AML patients harboring the same point muta-
tions, suggesting that context-specific expression of other
factors also strongly influences this outcome [16]. In an
MDS cell line expressing a mutant version of the SRSF2
splice factor, 487 genes were found to be differentially
spliced [17]. In general, SF3B1, SRSF2, and U2AF1 splice
factor mutations tend to promote exon skipping during
the splicing process as their ability to recognize specific
RNA 3′ splice site sequences is usually affected by the
mutation [5].
The SF3B1, SRSF2, and U2AF1 splice factor mutations
have garnered substantial attention due to their frequent,
though not indispensable, presence in myeloid neoplasms.
However, many other rare splice factor mutations such as
SF3A1 or PRPF40B can also exert widespread influence
on alternative splicing of target RNA sequences [9]. It has
been shown that spliceosome mutations tend to occur in
a mutually exclusive, rather than synergistic, manner [18],
suggesting a selective mechanism regulating the produc-
tion of alternate protein isoforms involved in cell function
and disease progression. However, not all splice factor
mutations have similar adverse associations with disease
development and patient prognosis as some are linked to
favorable clinical outcomes [11, 12].
Splicing in AML
Intriguingly, splice factor mutations are less common in
AML than MDS, despite AML sometimes arising from
an important transformative event in MDS progression
that occurs in about one third of MDS patients [19]. In
general, the prevalence of more common splice factor
mutations in AML is approximately 4 % for SF3B1,
4.9 % for SRSF2, and 6.4 % forU2AF1 [5]. In MDS pa-
tients, SF3B1 mutations are associated with better clin-
ical outcomes and reduced risk of AML development
[12]. In contrast, SRSF2 mutations predict shorter sur-
vival outcomes and greater risk of AML progression
[13]. U2AF1 mutations carry the greatest risk of progres-
sion to AML [19] and are associated with a lack of
remission and short survival outcomes in AML patients
[20]. Poor response to therapy and adverse patient
outcomes suggest that these aberrant splicing events
strongly influence tumor cell survival.
Accordingly, recent studies have demonstrated that al-
ternative splicing events may be a fundamental aspect of
AML disease biology. A genome-wide analysis of aber-
rant splicing patterns in AML patients showed that ap-
proximately one third of genes are differentially spliced
compared with CD34+ cells obtained from normal con-
trols [21]. In two study cohorts, totaling more than 200
AML patients, 135–786 recurrently spliced genes were
identified in each patient sample [21]. Approximately
76–80 % of these splicing changes could be mapped to
the translated transcript regions likely altering some as-
pects of protein function, while changes to the untrans-
lated region could affect transcript stability or translation
efficiency [21]. About half of the splice variants that were
identified had not been previously reported [21], suggest-
ing a disease-specific etiology. In multiple patient samples,
presence and abundance of some splice variants could
only be observed at diagnosis, disappeared during remis-
sion, and then strongly re-expressed during relapse [21].
Chemoresistance and apoptotic signaling
Chemoresistance in AML is often linked to defects in
the apoptotic signaling network. There are two well-
characterized pathways of apoptotic programmed cell
death that are distinguished by induction mechanisms
and specific molecular signaling events. The extrinsic
apoptotic pathway requires activation of a death receptor
on the cell surface which initiates CASP8 cleavage of
downstream executioner caspases [22]. In contrast, the in-
trinsic apoptotic pathway requires intracellular stress sig-
nals that induce mitochondrial membrane permeabilization
to activate CASP9 which then cleaves and activates the
downstream executioner caspases [23]. Mitochondrial
membrane susceptibility to permeabilization is primarily
controlled by the B cell lymphoma 2 (BCL-2) family of
proteins which has both pro- and anti-apoptotic members
that cumulatively regulate mitochondrial membrane integ-
rity [24]. Multiple studies have shown that basal expres-
sion levels of BCL-2 proteins can help predict response to
chemotherapeutic agents in AML [25, 26]. In particular,
overexpression of anti-apoptotic members of this protein
family is sufficient to establish tumor cell resistance to
multiple types of cytotoxic stimuli, although cell depend-
ence on a specific protein mechanism for survival varies
by treatment [25]. Similarly, upregulation of inhibitor of
apoptosis (IAP) protein members, which block apoptosis
by inhibiting caspase activity, is associated with chemore-
sistance in multiple types of cancers including AML [27].
SRSF1 splice factor
SRSF1 is an oncogenic splice factor that regulates spli-
cing of several proteins in the apoptotic pathway. SRSF1
overexpression was able to induce tumor formation in
epithelial cells and inhibit apoptosis in breast cancer
cells [28]. SRSF1 promotes alternative splicing of Bcl-2-
like protein 11 (BIM) producing isoforms lacking pro-
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apoptotic functions [28]. Furthermore, SRSF1 expression
is linked to mTORC1 activation [29] which is a signaling
pathway associated with AML progression and clonal
selection during re-propagation from minimal residual
disease [30]. Downregulation of SRSF1 in cervical carcin-
oma cells promoted pro-apoptotic splicing of MCL-1S,
BCL-XS, CASP9, and CASP2 variants [31]. Perhaps, this is
partially explained by a shift in the functional balance with
RBM4, a tumor suppressor splice factor that competitively
binds with SRSF1 to specific regulatory sequence elements
found in splicing locations of pre-mRNA [32]. In NSCLC
cells, overexpression of RBM4 was found to neutralize
SRSF1 to inhibit mTOR activation and induce apoptosis
by shifting BCL-X splicing to favor the pro-apoptotic
BCL-Xs isoform [32].
FLT3 pathway
One of the most common deregulated signaling mecha-
nisms in AML is that of FLT3, a tyrosine kinase receptor
that is frequently mutated and constitutively active in
about 25 % of AML patients [33]. Furthermore, FLT3 is
one of the most highly mis-spliced genes in AML with
aberrant splicing of the transcript primarily altering an
extracellular region of this receptor [34]. These alter-
ations are likely to be associated with AML pathogenesis
as certain FLT3 splice variants are strongly expressed
during diagnosis and relapse, but not detected during re-
mission, nor in other types of hematologic malignancies
[34]. Intriguingly, the production of FLT3 splice variants
is not associated with the presence of any specific splice
factor mutations [34] suggesting changes in expression
of regulatory spliceosome elements may promote these
events. FLT3 splice variants encode functional proteins
and affect critical downstream signaling targets (AKT,
STAT, ERK) which are highly activated in AML cells
producing aberrant FLT3 transcripts, even in the ab-
sence of an inducing FLT3 ligand [34]. Variable activa-
tion of downstream signals may help to explain why only
about 30 % of AML patients with activating FLT3-ITD
mutations become resistant to treatment with FLT3 inhib-
itors [33]. Previous research in our lab demonstrated that
AML cells with FLT3-ITD mutations that acquired resist-
ance to one type of FLT3 inhibitor were also resistant to
other structurally unrelated FLT3 inhibitors due to upreg-
ulation of a downstream STAT3-survivin pro-survival
pathway [35].
Survivin splice variants
Even when anti-apoptotic splice variants have a similar
cellular function, drug response can be altered by the ra-
tio of variants. Survivin is a protein that can inhibit
apoptosis by stabilizing other anti-apoptotic proteins
such as X-linked inhibitor of apoptosis protein (XIAP)
and sequestering pro-apoptotic proteins such as Smac/
Diablo [36, 37]. At least five alternative splice variants of
survivin have been reported that also conserve the XIAP
and Smac/Diablo protein binding regions but have dis-
tinct levels of association with chemoresistance and
other important clinico-pathological features in cancer
[38]. Presumably, any type of structural change can alter
the affinity and functional outcome of survivin interac-
tions. In addition, survivin splice variants have distinct
subcellular compartmentalization patterns that can shift
upon exposure to chemotherapy [39]. In HeLa cells
treated with etoposide, a mitochondrial accumulation of
survivin splice variant DeltaEx3 inhibited apoptosis by
preventing release of Smac/Diablo [39]. In AML pa-
tients, high expression of survivin-2B is significantly as-
sociated with risk of refractory disease and poor survival
outcomes in both children [40] and adults [41].
AKT activity and caspase-9 splicing
AKT activity has been linked to several aberrant splicing
mechanisms that promote chemoresistance, primarily
through modulation of CASP9 splicing. There are two al-
ternative splice variants of CASP9 distinguished by the in-
clusion (CASP9a) or exclusion (CASP9b) of a four-exon
cassette to create pro- or anti-apoptotic isoforms, respect-
ively [42]. In non-small cell lung cancer (NSCLC), AKT
phosphorylation of the splice factor srp30a (SRSF1) pro-
motes splicing of the anti-apoptotic isoform, CASP9b [42].
One of the exons excluded from anti-apoptotic CASP9,
exon 3, is found to differentially select through a competi-
tive interaction between the splicing enhancer hnRNPU
and repressor hnRNPL, which is influenced by AKT
activity [43]. AKT phosphorylation of hnRNPL displaces
hnRNPU at the exon 3 binding location of CASP9, effect-
ively decreasing the ratio of CASP 9a/b and enhancing the
tumorigenic potential of NSCLC cells [43]. Multiple
studies, including recent research in our lab, have demon-
strated that higher expression of AKT is associated with a
drug-resistant phenotype in AML [44].
WT1 and E2F1 transcription factors
Transcription factors can also have a critical regulatory
role in the splicing process and development of che-
moresistance. Wilms tumor 1 (WT1) is a zinc finger
transcription factor of important prognostic significance
in AML with four predominant splice isoforms, one of
which represses transcription of the SRPK1 splice factor
and alters VEGF splicing, promoting production of the
anti-angiogenic VEGF-A165b isoform [45]. While WT1
was originally identified as a tumor suppressor of kidney
cancer, its critical role in AML development in trans-
genic mice transduced with AML1-ETO [46], resistance
to death stimuli [47], and importance as a prognostic
marker of patient relapse and survival [48] demonstrate
its functions as an oncogene in AML. WT1 has been
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shown to interact directly with the splice factors RBM4,
U2AF2, and WTAP in an isoform-dependent manner,
which can influence splicing outcomes of their target
transcripts [45]. In fact, knockdown of WT1 expression
in AML cell lines promoted alternative splicing events
affecting approximately 1200 genes [47]. E2F transcrip-
tion factor 1 (E2F1) is another transcription factor that
influences apoptotic susceptibility of tumor cells by
regulating alternative splicing of apoptotic genes [49].
E2F1 has a role in induction of apoptosis caused by
DNA damaging agents, by upregulating expression of
the splicing factor SC35 (U2AF1) which promotes selec-
tion of the pro-apoptotic variants of FLICE-like inhibi-
tory protein (c-FLIP), CASP8, CASP9, and BCL-X [50].
Yet, while E2F1 may be an important tumor suppressor,
when this transcription factor interacts with cofactors
commonly expressed by tumor cells with defective cell
death signaling pathways, it participates in feedback
loops that can contribute to tumor aggressiveness and
chemoresistance [51]. It was shown that knockdown of
E2F1 resulted in approximately a 50 % decrease of cell
viability in chemoresistant lung adenocarcinoma cells
exposed to multiple therapeutics [52]. Therefore, E2F1
molecular targeting may be a beneficial therapeutic
strategy for certain aggressive tumor phenotypes.
Extrinsic apoptotic signals
Changes in expression of some splice factors such as
SPF45 can modify extrinsic apoptotic signaling mecha-
nisms in ways that lead to increased drug resistance
[53]. For example, overexpression of SPF45 in HeLa cells
resulted in up to a 21-fold increased resistance to mul-
tiple chemotherapeutics (carboplatin, vinorelbine, doxo-
rubicin, etoposide, mitoxantrone, and vincristine), while
SPF45 knockdown sensitized these tumor cells to some
treatment conditions [54]. One of the few identified spli-
cing targets of SPF45 is the Fas death receptor transcript
for which SPF45 promotes an exon skipping event to
produce a soluble anti-apoptotic protein isoform lacking
the transmembrane domain [53]. Nearly 200 genes have
been identified in mammalian cells that can modulate spli-
cing of Fas transcripts [55], and AML cells exposed to dif-
ferent chemotherapeutics dysregulate Fas splicing patterns
[56]. Elevated levels of soluble Fas in AML patient sera can
inhibit apoptosis of leukemic blasts by sequestering the
Fas ligand and have been associated with patient relapse
and resistance to therapy [57]. Fas death receptor signaling
can also be inhibited by alternative splicing of CASP8 and
production of an anti-apoptotic variant, CASP8L [58].
CASP8L is upregulated in hematopoietic progenitor cells
and minimally differentiated AML [59], characterized as a
particularly chemoresistant AML subtype [60]. A second
group of extensively studied death receptors with adverse
prognostic associations in AML are the TNF-related
apoptosis-inducing ligand (TRAIL) death receptors [61].
The IG20 gene, with a role in transduction of TRAIL
death receptor signals, produces four predominant splice
isoforms with contrary effects on apoptosis due to an abil-
ity to interfere with or promote CASP8 activation [62].
Anti-apoptotic IG20 splice variants (DENN) are expressed
at high levels in different types of leukemia cells causing
TRAIL associated apoptotic resistance [63].
c-FLIP
c-FLIP is another protein associated with chemoresistance
and cell survival that can interfere with activation of the
extrinsic apoptotic signaling pathway [64]. It is predomin-
antly expressed as two functional splice isoforms (c-FLIPL
and c-FLIPS) which block activation of CASP8 through
heterodimerization at different steps in the death induc-
tion signaling pathway [65] but can also have dual roles
depending on the physiological context. The longer iso-
form (c-FLIPL) inhibits apoptosis when expressed at high
concentrations but enhances CASP8 activation and pro-
motes apoptosis when expression levels are low [66]. In
AML, c-FLIP splicing patterns can have an important
prognostic value as the high expression levels of c-FLIPL,
but not c-FLIPs, are associated with significantly shorter
survival outcomes [67]. However, both c-FLIP isoforms
may be important therapeutic targets in AML since they
activate cytoprotective pathways involved in disease pro-
gression [64], and dual c-FLIP downregulation can induce
or sensitize AML cells to apoptosis [67].
Extrinsic and intrinsic apoptotic link
BH3 interacting-domain death agonist (BID) is a key player
in the apoptotic signaling network since it has the ability to
link the extrinsic to the intrinsic apoptotic pathways [22].
When CASP8 is activated by extrinsic death receptor sig-
naling, it can activate BID which then translocates to the
mitochondria and interacts with other pro-apoptotic BCL-2
members to promote intrinsic apoptosis [68]. However, al-
ternative splicing events are known to produce at least
four functional BID isoforms with distinct subcellular
localization patterns and conflicting apoptotic roles [69].
Pro-apoptotic BID is essential for normal hematopoiesis,
and BID-deficient mice spontaneously develop fatal mye-
loid neoplasms indicating that BID is necessary to sup-
press leukemogenesis [70]. The presence of pro-apoptotic
BID can also determine tumor cell susceptibility to extrin-
sic apoptotic stimuli [71], suggesting that both quantity
and ratio of BID splice variants can strongly influence
AML development and chemoresistance.
Anti-apoptotic BCL-2 proteins
Aberrant splicing of several BCL-2 family members is
known to promote drug resistance in AML. In this fam-
ily, MCL-1, BCL-X, and BID have splice variants coding
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for protein isoforms with contrary apoptotic functions
[68]. The predominantly expressed MCL-1 and BCL-X
proteins are the longer anti-apoptotic isoforms (MCL-1L
and BCL-XL) that can bind pro-apoptotic BAK prevent-
ing its oligerimerization and permeabilization of the
mitochondrial membrane [72]. MCL-1L can also seques-
ter pro-apoptotic proteins BIM and BID and, among
multiple anti-apoptotic BCL-2 members, was found to
be a critical regulator of AML cell survival [72]. MCL-1
splicing is partially regulated by SF3B1, and inhibition of
SF3B1 reversed the dominant splice isoform from anti-
apoptotic MCL-1L to pro-apoptotic MCL-1S in NSCLC
[73] and cervical carcinoma cell models [31]. Our re-
search group recently demonstrated that exposure to
YM155 significantly upregulated expression of MCL-1S
in AML cells sensitive to this treatment [44], although a
splice factor mechanism modulating this event was not
identified. However, other researchers have demonstrated
that some drugs that block tumor growth and induce cell
cycle arrest promote production of pro-apoptotic MCL-1S
and BCL-XS variants through downregulation of the
AS/SF2 (SRSF1) splice factor [31].
Pro-apoptotic BCL-2
Alternative splicing of BH3-only pro-apoptotic BCL-2
proteins found in the intrinsic apoptotic signaling path-
way can also contribute to a chemoresistant phenotype
in AML. Among these BCL-2 members, only BIM and
p53 upregulated modulator of apoptosis (PUMA) have a
strong affinity to all anti-apoptotic BCL-2 proteins
(BCL-2, BCL-XL, BCL-W, MCL-1, and A1), while BAD,
BIK, HRK, and NOXA selectively heterodimerize with a
limited number of anti-apoptotic members [74]. BIM
has multiple alternative splice isoforms having distinct
pro-apoptotic mechanisms due to altered protein hetero-
dimerization abilities [75] and mitochondrial localization
patterns [76]. In one study, inhibition of any of the three
major BIM isoforms resulted in different levels of resist-
ance to glucocorticoid treatment in leukemia cells [77].
Comparably, an intronic deletion in the BIM gene was
found to promote production of an anti-apoptotic BH3-
deficient splice isoform which was associated with resist-
ance to tyrosine kinase inhibitor treatment in leukemia
cell lines [78]. Similarly, NOXA also has at least two
splice variants lacking the BH3 region which eliminates
their ability to bind to other BCL-2 family proteins and
results in a loss of pro-apoptotic activity [79].
Other apoptotic regulators
Alternative splicing of many other proteins with regula-
tory roles in the apoptotic signaling network can enhance
pro- or anti-apoptotic characteristics and influence che-
moresistance. For example, a pro-apoptotic Smac3 splice
variant of Smac/Diablo was found to accelerate XIAP
autoubiquitination and destruction and enhanced apop-
totic cell death in HeLa cells exposed to multiple chemo-
therapeutics [80]. XAF1 is a pro-apoptotic protein that
also targets XIAP and can enhance tumor cell susceptibil-
ity to cisplatin [81] and radiotherapy [82]. While XAF1 ex-
pression in tumor cells is generally very low, quantities of
alternatively spliced truncated isoforms lacking the XIAP
interaction have been found to increase in some aggressive
cancers and have been suggested as potential biomarkers
of disease status [83, 84]. Frequently, when alternatively
spliced isoforms have opposing functions, the ratio of one
isoform to another is associated with a cancer treatment
phenotype. For example, expression of anti-apoptotic
neuronal apoptosis inhibitory protein (NAIP) relative to
its less effective splice variant NAIP-DEx3 increases sub-
stantially in chemoresistant AML cell lines [85]. Intri-
guingly, one study performed with AML blasts from
patients with relapsed chemoresistant AML, found the
p75 splice variant of the lens epithelial-derived growth fac-
tor (LEDGF) protein to be the most consistently upregu-
lated transcript in these cells [86]. LEDGF p75 is a stress
oncoprotein that promotes chemoresistance but has an
antagonistic splice isoform, LEDGF p52, that can promote
apoptosis in tumor cells [87].
Splice variant targeting therapies
A number of natural products derived from distinct spe-
cies of bacteria have been found to target the SF3B
component of the spliceosome and demonstrate potent an-
titumor activities [88]. One of the first to be identified was
FR901464, a fermentation product from Pseudomonas,
which has been used as a structural model for the synthesis
of several stable chemical analogs of similar or greater po-
tency [89]. In particular, meayamycin B, a soluble synthetic
FR901464 derivative, can significantly inhibit tumor growth
at low picomolar concentrations and demonstrates import-
ant potential for development as a novel therapy for AML
treatment [90]. Meayamycin B inhibits the SF3B1 subunit
and can shift alternative splicing of MCL-1 to promote ex-
pression of the pro-apoptotic MCL-1s isoform [73]. Al-
though SF3B1 is among the most commonly mutated
splice factors both in MDS and AML, these mutations are
not located in the putative binding region of spliceosome
inhibitors like meayamycin B, suggesting that they could
be effective therapeutic options for patients with these mu-
tations [91].
Conclusions
In AML, generation of functional protein products with
oncogenic qualities is largely determined by regulation of
transcript expression levels and alternative splicing events
[92]. Upregulation of pro-survival pathways, oncogenic
transcription factors, intrinsic and extrinsic apoptotic sig-
nals, and production of altered death effector molecules
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are all important elements that can be altered by splicing
events to establish a chemoresistant phenotype. During
AML development, increasingly oncogenic transforma-
tions of a hematopoietic cell eventually result in prolifera-
tion of a founding clone and usually the presence of at
least one subclone [93]. AML cells acquire additional mu-
tations during disease progression in a process of clonal
selection that can be strongly influenced by treatment
such that a cytogenetically distinct clone is present at re-
lapse [94]. During this process of clonal evolution, muta-
tions causing dysregulation of alternative splicing events
that confer tumor cell survival advantages can become im-
portant drivers of leukemogenesis and drug resistance [9].
AML patients with the highest rates of splice factor muta-
tions share a common disease ontogeny characterized by
a high incidence of treatment failure [95]. Although
splice-typing is not yet a widespread method of AML clas-
sification or risk stratification, the potential to develop
these analyses merits further evaluation. As understanding
of splicing dysregulation in this disease grows, new thera-
peutic targets may become evident. Ultimately, treatment
strategies that target key spliceosome elements such as
SF3B1 or specific oncogenic splice variants in a man-
ner that circumvents the resistance mechanism may
prove to be valuable methods to eradicate these types
of AML clones.
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